Table 2.
Patient treatment characteristics.
| Patient | Age at recurrence (years) | Time to recurrenceb (years) | Histology of breast tumor | Type of recurrence | Subtype | IBTR size (cm) | Lymph node sampling | Adjuvant systemic therapy |
|---|---|---|---|---|---|---|---|---|
| 1 | 78 | 25 | IDC | IBTR | ER/PR+ | 0.2 | 0/3 | Exemestane |
| 2 | 74 | 36 | IDC | PBC | PR+ | 0.2 | – | Intolerance of AI |
| 3 | 60 | 16 | DCIS | IBTR | PR+ | 0a | – | None |
| 4 | 85 | 9 | IDC | IBTR | ER/PR+ | 0.4 | – | None, previous intolerance of AI |
| 5 | 78 | 29 | DCIS | IBTR | ER/PR+ | 0.6 | – | Tamoxifen |
| 6 | 52 | 0.2 | IDC | PBC | ER/PR+ | 3.5 | 5/20 | TC, anastrazole |
| 7 | 64 | 21 | IDC | SBC | PR+ | 1.1 | 0/2 | Anastrazole |
| 8 | 66 | 46 | DCIS | PBC | ER/PR− | 0.5 | – | None |
| 9 | 64 | 11 | IDC | SBC | ER/PR+ | 1.5 | 0/3 | Anastrazole but did not tolerate |
| 10 | 55 | 5 | Mixed IDC/ILC | IBTR | ER/PR+ | 1.9 | 0/14 | Letrozole |
| 11 | 78 | 19 | IDC | SBC | ER/PR+, HER2+ | 3.9 | – | Anastrazole, trastuzumab |
| 12 | 62 | 8 | IDC | SBC | ER/PR+, HER2+ | 0.4 | 0/1 | Anastrazole, trastuzumab |
IBTR, ipsilateral breast tumor recurrence; SBC, second breast cancer defined as an ipsilateral breast cancer of a different histology from the initial primary breast cancer; PBC, primary breast cancer in the setting of another prior malignancy; AI, aromatase inhibitor; TC, docetaxel and cyclophosphamide.
aPatient 3 had no residual disease at the time of lumpectomy.
bInterval time from prior diagnosis to biopsy-proven breast recurrence.